ARL8B

Across TCGA pan-cancer cohorts, ARL8B RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated ARL8B data layer compared with 3 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ARL8B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL8B expression acts as an unfavorable survival marker, although some lineages such as KIRC and LUAD show a favorable association.

LIHC, MESO, and KICH are the cancer types where ARL8B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.410	0.630	<.001	77	view →
MESO	DFS	Median	III,IV	0.298	0.518	.008	44	view →
KICH	DFS	Tertile	All	0.729	1.000	.004	42	view →
SCLC	OS	Median	All	0.469	1.000	.001	38	view →
KIRC	OS	Tertile	All	0.701	0.529	.001	36	view →
LUAD	OS	Tertile	II,III,IV	0.684	0.354	.010	35	view →
PAAD	OS	Quartile	All	0.183	0.645	.001	25	view →
ACC	DFS	Median	II,III,IV	0.174	0.600	.005	24	view →
STAD	DFS	Quartile	IV	0.251	0.769	.014	21	view →
UCS	DFS	Tertile	IV	0.860	0.323	.024	18	view →
SKCM	DFS	Quartile	II,III,IV	0.342	0.158	.002	15	view →
ESCA	OS	Quartile	III,IV	0.645	0.309	.008	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

ARL8B–LIHC (DFS)

Open the LIHC breakdown →